Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | Safety and efficacy of allogeneic CAR-T cell treatment

Sattva Neelapu • 29 May 2020
ASCO 2020
Non-Hodgkin Lymphoma ALLO-501 ALLO-647
ALPHA

Sattva Neelapu, MD, University of Texas MD Anderson Cancer Center, Houston, TX, evaluates the safety and efficacy of allogeneic CAR-T cell treatment in the ALPHA study (NCT03939026) involving non-Hodgkin’s lymphoma patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Sattva Neelapu

Five-year follow-up of the ZUMA-5 trial investigating axi-cel in R/R indolent NHL
4:50
Five-year follow-up of the ZUMA-5 trial investigating axi-cel in R/R indolent NHL
Sattva Neelapu • 12 Dec 2024
Next steps with ADI-001
0:42
Next steps with ADI-001
Sattva Neelapu • 5 Jun 2022
ZUMA-12: axi-cel as first-line therapy in high-risk large B-cell lymphoma
2:06
ZUMA-12: axi-cel as first-line therapy in high-risk large B-cell lymphoma
Sattva Neelapu • 5 Jun 2022
ADI-001: anti-CD20 CAR-engineered allogeneic γδ T cells in adults with B-cell malignancies
3:24
ADI-001: anti-CD20 CAR-engineered allogeneic γδ T cells in adults with B-cell malignancies
Sattva Neelapu • 5 Jun 2022

Related Videos

Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
2:13
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
Mary Jo Lechowicz • 11 Sep 2026
Key advances in FL management expected to change practice over the next five years
1:26
Key advances in FL management expected to change practice over the next five years
Kim Linton • 11 Sep 2026
Community lymphoma management: which patients should be prioritized for specialist referral?
1:16
Community lymphoma management: which patients should be prioritized for specialist referral?
Nirav Niranjan Shah • 10 Sep 2026
The content of VJHemOnc is intended for healthcare professionals